Business Context and Reporting Period
Company: Inspire Medical Systems, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 9, 2026 (Earliest event reported)
Reporting Period: The filing references preliminary and unaudited results for the quarter and full year ended December 31, 2025, announced via press release on January 12, 2026.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained in the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the provided text.
Material Changes and Executive Transitions
- Appointment of New CFO: The Board appointed Matthew J. Osberg as Chief Financial Officer, effective the day after the filing of the 2025 Annual Report on Form 10-K. Mr. Osberg will also serve as principal financial and accounting officer.
- Interim CFO Arrangement: Richard J. Buchholz, who stepped down as CFO in August 2025, was appointed Interim CFO on January 9, 2026, to serve through the filing of the 2025 10-K.
- Compensation Details for Mr. Osberg:
- Annual Base Salary: $650,000.
- Target Annual Cash Bonus: 70% of base salary.
- Sign-on Bonus: $600,000 (paid in two installments).
- Long-Term Incentives: Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) each with a target value of $1,500,000.
- Severance: 12 months of base salary plus target bonus upon termination without Cause, with acceleration of equity awards in Change of Control scenarios.
Guidance, Outlook, and Risks
Outlook and Guidance: The filing states that preliminary financial results for 2025 are subject to change based on closing procedures and internal control reviews. The Company plans to participate in investor and analyst meetings in January 2026, with presentation materials furnished as Exhibit 99.2.
Risks and Contingencies: The filing notes that the preliminary financial results are unaudited and subject to revision. No specific new risk factors or contingencies are detailed in the text provided, other than the standard caveats regarding the transition of financial leadership and the preliminary nature of the reported results.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific 2025 revenue, net income, and cash flow figures.
- Verify the exact effective date of Matthew J. Osberg's CFO role relative to the 2025 10-K filing date.
- Examine the Investor Presentation (Exhibit 99.2) for updated forward-looking guidance and strategic priorities.
- Confirm the terms of the Transition and Separation Agreement with Richard J. Buchholz to ensure no additional undisclosed liabilities.
- Monitor the upcoming 10-K filing for the final audited financial statements and the formal appointment of the new CFO.